|Bid||0.00 x 0|
|Ask||0.00 x 0|
|Day's Range||46.92 - 47.46|
|52 Week Range||36.39 - 58.37|
|PE Ratio (TTM)||18.61|
|Forward Dividend & Yield||1.28 (2.61%)|
|1y Target Est||N/A|
Novartis AG (NVS) reported revenue of $12.9 billion and EPS (earnings per share) of $1.21 in 4Q17, a 4.8% rise in revenue compared to 4Q16. For 1Q18, analysts expect Novartis to see EPS of $1.28 on revenue of $12.6 billion.
Alcon, Novartis’s (NVS) eye care business, includes surgical products and vision care products. Alcon products are marketed in over 180 countries worldwide. Alcon is expected to report growth in revenue following increased demand for contact lenses and surgical products in 1Q18.
Novartis’s (NVS) Innovative Medicines segment includes cardio-metabolic products, oncology products, immunology and dermatology products, respiratory products, neuroscience products, and established products.
Novo Nordisk (NVO) is a global pharmaceutical company dealing with discovery, development, manufacturing, and commercialization of pharmaceutical products. The company has segregated its business into two segments: Diabetes & Obesity Care and Biopharmaceuticals.
Novo Nordisk (NVO) secures a global licence for United States' biotech company EpiDestiny's sickle cell disease program EPI01.
Danish drugmaker Novo Nordisk has secured the global licence for U.S. biotech company EpiDestiny's sickle cell disease (SCD) programme in a bid to offset declining sales in its biopharmaceutical business. Novo, best known for its diabetes drugs, is on the hunt for promising assets to boost its struggling blood products business after it lost out to French rival Sanofi in the chase for Belgian biotech company Ablynx in January. "This is a great opportunity for Novo Nordisk to enter into a new therapeutic area closely related to our existing biopharmaceutical business," said chief scientific officer Mads Krogsgaard Thomsen.
A dozen drugs launching in 2018 from heavy-hitters like Roche, Gilead and J&J are expected to hit blockbuster status over the next five years, an analytics firm predicted Thursday.
The 30 most obese countries in the world in 2018 represent a huge (pun intended) market opportunity for weight loss drugmakers. Increasingly sedentary lifestyles and a lack of healthy eating habits among large swaths of the global population have resulted in dramatically rising obesity rates in the past few decades, particularly in urban settings. Obesity is […]
Leading diabetes drugmaker Novo Nordisk (NOVOb.CO) has named former oil boss Helge Lund as its new chairman as the company contends with increasing price pressure and seeks acquisitions to broaden its blood products line-up. The man dubbed by some as Norway's Mr Oil because of his extensive career in the oil and gas industry may be more of an expert in hydrocarbons than insulin, but his merger and acquisitions experience is a big draw for the Danish pharmaceuticals company.
Based on readouts from this study, the company plans to evaluate the efficacy and safety of once-a-week semaglutide therapy in NASH indications in its Phase 3 trial. According to a Diabetes Care report, ~80% of NASH patients suffer from obesity.
In 2017, Novo Nordisk’s (NVO) Saxenda sales reached 2.6 billion Danish kroner, a YoY (year-over-year) rise of 64% in local currencies. According to IQVIA, by the end of November 2017, Saxenda accounted for 79%, 86%, 72%, 52%, 47%, 40%, 30%, 19%, 14%, and 6% of the total value of anti-obesity medications sold in the United Arab Emirates, Canada, Denmark, the United States, Italy, Spain, Brazil, Germany, Australia, and Mexico, respectively. In December 2017, Novo Nordisk submitted an application to the FDA seeking an update to Saxenda’s label to include data from the LEADER trial.
Novo Nordisk’s (NVO) Xultophy reported sales close to 729 million Danish kroner in 2017, a 252% YoY (year-over-year) rise on a reported basis and a 255% YoY rise in local currencies. The uptake of Xultophy, a combination of Tresiba and Victoza, was mainly driven by increasing demand in European and North American markets. Xultophy secured approval from the FDA on November 21, 2016, as a once-daily injectable adjunct therapy for type 2 diabetes patients who don’t respond adequately to a daily intake of 50 units of basal insulin or up to 1.8 mg of Victoza (liraglutide).
Novo Nordisk (NVO) has been creating awareness about the risks of hypoglycemia and the benefits of Tresiba among GPs (general practitioner) and PCPs (primary care physician). Patients suffering from type 1 diabetes are generally treated by endocrinologists, who focus on factors such as low intra-patient glycemic variability, a flat and stable drug profile, fewer hypoglycemia events, patient convenience, and confidence in the product while prescribing drugs. Because GPs and PCPs don’t focus on glycemic variability and hypoglycemia events, Novo Nordisk’s efforts to raise awareness are expected to drive the adoption of Tresiba in the type 2 diabetes patient population.
Novo Nordisk (NVO) is anticipating the FDA’s decision related to the inclusion of hypoglycemia data from its DEVOTE and SWITCH studies by the end of 1Q18. In 4Q17, the company also submitted a supplemental application to the Japanese Ministry of Health, Labour and Welfare for updating Tresiba’s label to reflect hypoglycemia data from the DEVOTE trial. Novo Nordisk is anticipating a readout of the results from its trial comparing Tresiba to insulin glargine U300 in 4Q18.
In 2017, Novo Nordisk’s (NVO) basal insulin therapy, Tresiba, reported revenue of nearly 7.3 billion Danish kroner and attained blockbuster status. The drug has witnessed rapid uptake in markets in which it has par access compared to competing products, such as insulin glargine U100. In the United States, Novo Nordisk managed to attain a 34% share of the total basal insulin market by volume as of January 2018.
Novo Nordisk (NVO) has adopted a market-fit strategy, offering insulin products that are suitable for the different demands of patients in different geographies. The company considers affordability to be the key commercial aspect of its human insulin portfolio, which mainly caters to diabetes patients with lower purchasing power. Novo Nordisk believes that high familiarity owing to long-term presence in the market is a major competitive advantage for its modern insulin portfolio.
According to the International Diabetes Federation, ~10% of adults in the world are affected by diabetes. Of these, 11.2 million patients are estimated to be treated with the company’s human insulin products, 12.5 million with its modern insulin products, 0.9 million with its new-generation insulin products, and the remaining 1.4 million with its glucagon-like peptide 1 (or GLP-1) products.